Shenzhen Hepalink Pharmaceutical Co Ltd (002399) — Working Capital to Net Assets Ratio
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Working Capital to Net Assets ratio of 41.9% as of March 2026. Working capital of CN¥5.13 Billion (current assets of CN¥9.58 Billion minus current liabilities of CN¥4.45 Billion) is measured against net assets of CN¥12.23 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shenzhen Hepalink Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shenzhen Hepalink Pharmaceutical Co Ltd Working Capital to Net Assets (2006–2025)
This chart shows how Shenzhen Hepalink Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the ratio stands at 41.9%, reflecting working capital of CN¥5.13 Billion against net assets of CN¥12.23 Billion CNY. Check tangible equity quality of Shenzhen Hepalink Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Shenzhen Hepalink Pharmaceutical Co Ltd worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 43.0% | CN¥5.20 Billion | CN¥12.08 Billion | CN¥9.15 Billion | CN¥3.95 Billion | ▼ -5.5 pp |
| 2024 | 48.5% | CN¥5.92 Billion | CN¥12.20 Billion | CN¥9.62 Billion | CN¥3.70 Billion | ▲ +1.7 pp |
| 2023 | 46.9% | CN¥5.62 Billion | CN¥11.99 Billion | CN¥10.60 Billion | CN¥4.99 Billion | ▼ -8.1 pp |
| 2022 | 54.9% | CN¥6.81 Billion | CN¥12.41 Billion | CN¥12.39 Billion | CN¥5.58 Billion | ▲ +3.0 pp |
| 2021 | 51.9% | CN¥5.98 Billion | CN¥11.52 Billion | CN¥10.77 Billion | CN¥4.79 Billion | ▲ +4.7 pp |
| 2020 | 47.2% | CN¥5.52 Billion | CN¥11.69 Billion | CN¥9.13 Billion | CN¥3.61 Billion | ▲ +33.4 pp |
| 2019 | 13.8% | CN¥1.03 Billion | CN¥7.47 Billion | CN¥6.00 Billion | CN¥4.97 Billion | ▼ -3.8 pp |
| 2018 | 17.5% | CN¥1.10 Billion | CN¥6.24 Billion | CN¥5.60 Billion | CN¥4.50 Billion | ▼ -19.9 pp |
| 2017 | 37.5% | CN¥2.88 Billion | CN¥7.69 Billion | CN¥6.13 Billion | CN¥3.25 Billion | ▼ -19.9 pp |
| 2016 | 57.3% | CN¥4.64 Billion | CN¥8.09 Billion | CN¥6.70 Billion | CN¥2.07 Billion | ▼ -5.9 pp |
| 2015 | 63.2% | CN¥5.56 Billion | CN¥8.79 Billion | CN¥6.48 Billion | CN¥920.48 Million | ▼ -15.4 pp |
| 2014 | 78.7% | CN¥6.57 Billion | CN¥8.35 Billion | CN¥6.76 Billion | CN¥186.28 Million | ▼ -8.7 pp |
| 2013 | 87.3% | CN¥7.05 Billion | CN¥8.07 Billion | CN¥7.18 Billion | CN¥132.02 Million | ▼ -6.8 pp |
| 2012 | 94.2% | CN¥7.58 Billion | CN¥8.05 Billion | CN¥7.75 Billion | CN¥171.48 Million | ▼ -2.8 pp |
| 2011 | 97.0% | CN¥7.68 Billion | CN¥7.91 Billion | CN¥7.72 Billion | CN¥40.43 Million | ▼ -1.4 pp |
| 2010 | 98.4% | CN¥7.90 Billion | CN¥8.02 Billion | CN¥7.99 Billion | CN¥91.98 Million | ▲ +2.7 pp |
| 2009 | 95.8% | CN¥1.02 Billion | CN¥1.07 Billion | CN¥1.26 Billion | CN¥230.14 Million | ▼ -14.0 pp |
| 2008 | 109.7% | CN¥337.83 Million | CN¥307.83 Million | CN¥530.11 Million | CN¥192.29 Million | ▼ -16.3 pp |
| 2007 | 126.1% | CN¥184.60 Million | CN¥146.44 Million | CN¥212.73 Million | CN¥28.13 Million | ▼ -64.4 pp |
| 2006 | 190.5% | CN¥173.95 Million | CN¥91.33 Million | CN¥310.10 Million | CN¥136.15 Million | — |